Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

First-line immune checkpoint inhibitor-based combinations in unresectable hepatocellular carcinoma: current management and future challenges
Alessandro Rizzo, Angela Dalia Ricci, Gennaro Gadaleta‐Caldarola, et al.
Expert Review of Gastroenterology & Hepatology (2021) Vol. 15, Iss. 11, pp. 1245-1251
Closed Access | Times Cited: 81

Showing 1-25 of 81 citing articles:

Tumor cell plasticity in targeted therapy-induced resistance: mechanisms and new strategies
Zhenduo Shi, Kun Pang, Zhuo‐Xun Wu, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 93
Which role for predictors of response to immune checkpoint inhibitors in hepatocellular carcinoma?
Alessandro Rizzo, Antonio Cusmai, Gennaro Gadaleta‐Caldarola, et al.
Expert Review of Gastroenterology & Hepatology (2022) Vol. 16, Iss. 4, pp. 333-339
Closed Access | Times Cited: 79
Trans-Arterial Chemoembolization Plus Systemic Treatments for Hepatocellular Carcinoma: An Update
Alessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
Journal of Personalized Medicine (2022) Vol. 12, Iss. 11, pp. 1788-1788
Open Access | Times Cited: 57
Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma
Yue Chen, Haoyue Hu, Xianglei Yuan, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 44
Disulfiram/Copper Induces Immunogenic Cell Death and Enhances CD47 Blockade in Hepatocellular Carcinoma
Xingxing Gao, Hechen Huang, Caixu Pan, et al.
Cancers (2022) Vol. 14, Iss. 19, pp. 4715-4715
Open Access | Times Cited: 35
Challenges and Future Trends of Hepatocellular Carcinoma Immunotherapy
Alessandro Rizzo, Angela Dalia Ricci
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 19, pp. 11363-11363
Open Access | Times Cited: 27
Tremelimumab and Durvalumab in the Treatment of Unresectable, Advanced Hepatocellular Carcinoma
Tiago Biachi De Castria, Danny N. Khalil, James J. Harding, et al.
Future Oncology (2022) Vol. 18, Iss. 33, pp. 3769-3782
Closed Access | Times Cited: 26
Lenvatinib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
Shijie Wang, Yiting Wang, Jiangtao Yu, et al.
Cancers (2022) Vol. 14, Iss. 22, pp. 5525-5525
Open Access | Times Cited: 22
Advanced lung cancer inflammation index predicts survival outcomes of hepatocellular carcinoma patients receiving immunotherapy
Qian Li, Fei Ma, Ju feng Wang
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 14
An exosome-related lncRNA signature correlates with prognosis, immune microenvironment, and therapeutic responses in hepatocellular carcinoma
Peng Wang, Shuya Bai, Mengli Zheng, et al.
Translational Oncology (2023) Vol. 31, pp. 101651-101651
Open Access | Times Cited: 14
Enhancing HCC Treatment: innovatively combining HDAC2 inhibitor with PD-1/PD-L1 inhibition
Rui Han, Changquan Ling, Yuqian Wang, et al.
Cancer Cell International (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 14
Emerging trends and thematic evolution of immunotherapy for glioma based on the top 100 cited articles
Yan Zhou, Min Liu, Xing Huang, et al.
Frontiers in Oncology (2024) Vol. 13
Open Access | Times Cited: 4
Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: A systematic review and meta-analysis
Jiaxi Zheng, Minghai Shao, Weifang Yang, et al.
International Immunopharmacology (2022) Vol. 112, pp. 109244-109244
Open Access | Times Cited: 21
The Role of the NLRP3 Inflammasome in HCC Carcinogenesis and Treatment: Harnessing Innate Immunity
Stavros P. Papadakos, Nikolaos Dedes, Elias Kouroumalis, et al.
Cancers (2022) Vol. 14, Iss. 13, pp. 3150-3150
Open Access | Times Cited: 19
Tumor Microenvironment in Hepatocellular Carcinoma: Key Players for Immunotherapy
Hai Feng, Yunhui Zhuo, Xuemei Zhang, et al.
Journal of Hepatocellular Carcinoma (2022) Vol. Volume 9, pp. 1109-1125
Open Access | Times Cited: 19
Exploring pathological signatures for predicting the recurrence of early-stage hepatocellular carcinoma based on deep learning
Wei‐Feng Qu, Meng‐Xin Tian, Jingtao Qiu, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 18
Interim efficacy and safety of PD-1 inhibitors in preventing recurrence of hepatocellular carcinoma after interventional therapy
Wenying Qiao, Qi Wang, Caixia Hu, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 17
All-trans-retinoic acid inhibits hepatocellular carcinoma progression by targeting myeloid-derived suppressor cells and inhibiting angiogenesis
Xueyan Li, Xiaoqi Luo, Siru Chen, et al.
International Immunopharmacology (2023) Vol. 121, pp. 110413-110413
Closed Access | Times Cited: 10
Anlotinib Combined With Toripalimab as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Prospective, Multicenter, Phase II Study
Chengsheng Zhang, Zhiming Zeng, Manyun Zhuo, et al.
The Oncologist (2023) Vol. 28, Iss. 12, pp. e1239-e1247
Open Access | Times Cited: 10
YAP1 suppression inhibits autophagy and improves the efficacy of anti-PD-1 immunotherapy in hepatocellular carcinoma
Yuting Gao, Qing Peng, Shenghao Li, et al.
Experimental Cell Research (2023) Vol. 424, Iss. 1, pp. 113486-113486
Closed Access | Times Cited: 9
CEUS LI-RADS for diagnosis of hepatocellular carcinoma in individuals without LI-RADS-defined hepatocellular carcinoma risk factors
Zhe Huang, Ping Zhou, Shan Shan Li, et al.
Cancer Imaging (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 9
Unraveling the Significance of EPH/Ephrin Signaling in Liver Cancer: Insights into Tumor Progression and Therapeutic Implications
Stavros P. Papadakos, Ioanna Ε. Stergiou, Nikolina Gkolemi, et al.
Cancers (2023) Vol. 15, Iss. 13, pp. 3434-3434
Open Access | Times Cited: 9
Correlation between surrogate endpoints and overall survival in unresectable hepatocellular carcinoma patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis
Litao Huang, Deying Kang, Chongyang Zhao, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 3
Clinical outcomes of PD-1/PD-L1 inhibitors in patients with advanced hepatocellular carcinoma: a systematic review and meta-analysis
Wen Wen, Yong Zhang, Hua Zhang, et al.
Journal of Cancer Research and Clinical Oncology (2022) Vol. 149, Iss. 3, pp. 969-978
Closed Access | Times Cited: 15
Hu Antigen R (HuR) Protein Structure, Function and Regulation in Hepatobiliary Tumors
Sofía Lachiondo‐Ortega, Teresa C. Delgado, Blanca Baños‐Jaime, et al.
Cancers (2022) Vol. 14, Iss. 11, pp. 2666-2666
Open Access | Times Cited: 13
Page 1 - Next Page

Scroll to top